Risultati per: Linee-guida GOLD 2023,cosa cambia?
Questo è quello che abbiamo trovato per te
Linea guida aggiornata per la gestione dell’osteartrosi dell’anca.
Farmaceutiche, Valentino Confalone alla guida di EuniPharma
Rappresenta le aziende a capitale europeo e nipponico
'Mai più handicappato', cambia la lingua della disabilità
Effetti su documenti.Nell’Osservatorio gruppo ‘Donne e violenza’
Italiani sempre più celiaci, ecco le linee guida per terapia
Sono 224mila i casi diagnosticati, ma si stimano circa 600mila
Boom di trapianti nel 2023, superati i 4 mila interventi
In Italia mai così tanti. Schillaci: ‘Rafforzare la cultura della donazione’
Oms Europa, nel 2023 i casi di morbillo sono aumentati di 30 volte
Dopo 60 anni, da quando il primo vaccino contro la malattia è stato autorizzato, l’Agenzia lancia un alert per il verificarsi di possibili epidemie laddove manchino le coperture vaccinali
Italiani sempre più celiaci, ecco le linee guida per terapia
Sono 224mila i casi diagnosticati, ma si stimano circa 600mila
A New Equilibrium for Telemedicine: Prevalence of In-Person, Video-Based, and Telephone-Based Care in the Veterans Health Administration, 2019–2023
Annals of Internal Medicine, Ahead of Print.
A New Equilibrium for Telemedicine: Prevalence of In-Person, Video-Based, and Telephone-Based Care in the Veterans Health Administration, 2019–2023
Annals of Internal Medicine, Ahead of Print.
Linee guida sul trattamento sistemico del cancro al seno metastatico
Società Italiana d’Igiene: “guida alle buone pratiche vaccinali”
Linee guida sulla diagnosi e la gestione del cancro al seno precoce e localmente avanzato
NEJM Journal Watch General Medicine 2023 Audio Year in Review
Listen as Dr. Allan Brett and other editors discuss the most important medical research of 2023.
Ministero sanità Malawi, 10.000 morti per malattia nel 2023
Malaria resta maggiore causa di morte infantile
Notice of Retraction: Worthington MA, et al. Dynamic Prediction of Outcomes for Youth at Clinical High Risk for Psychosis: A Joint Modeling Approach. JAMA Psychiatry. 2023;80(10):1017-1025.
To the Editor In consulting with another group attempting to replicate our analyses, we have identified a coding error in the joint modeling analyses in our article, “Dynamic Prediction of Outcomes for Youth at Clinical High Risk for Psychosis: A Joint Modeling Approach,” published online on August 2, 2023, and in the October 2023 issue of JAMA Psychiatry. Specifically, the converter by time interaction term used in the feature selection phase of the longitudinal mixed-effects analyses was mistakenly retained in the longitudinal mixed-effects component of the joint models, but only the time effect should have been used in this phase. As a result of this error, the short-term longitudinal features used to boost performance of the baseline prediction models contained information on the outcomes to be predicted, making them not about prediction per se but about describing differential change as a function of outcome. The results for the base models and the feature selection stage are correct, but the results for the joint models that combine the base models and the selected longitudinal features are subject to this error. When the joint model analyses were rerun with the correct coding, they no longer showed improved prediction accuracy over and above the performance of the Cox regression models incorporating baseline-only predictors. Because the primary significance and novelty of the article were based on improved prediction in joint models incorporating information on short-term clinical change, we have requested that the article be retracted. Until studies of new samples are completed, short-term (baseline to 2-month) clinical change cannot be used to boost the performance of baseline-only prediction models of psychosis and remission of clinical high-risk status. We apologize for any confusion this error may have caused.